Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total value of $87,455.08. Following the transaction, the director now owns 7,066,113 shares of the company’s stock, valued at $53,985,103.32. This trade represents a 0.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, October 29th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.72, for a total value of $76,923.84.
• On Tuesday, October 15th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.67, for a total value of $76,351.49.
• On Tuesday, October 1st, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.22, for a total transaction of $71,200.34.
• On Tuesday, September 17th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.84, for a total transaction of $78,297.48.
• On Tuesday, September 3rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.27, for a total transaction of $71,772.69.
• On Tuesday, August 20th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.12, for a total value of $81,502.64.

Recursion Pharmaceuticals Stock Down 10.6 %

NASDAQ:RXRX opened at $6.18 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock has a market capitalization of $1.74 billion, a P/E ratio of -4.04 and a beta of 0.81. The company’s 50-day simple moving average is $6.66 and its 200-day simple moving average is $7.60. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $5.89 and a fifty-two week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the prior year, the firm posted ($0.43) earnings per share. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% compared to the same quarter last year. On average, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Axxcess Wealth Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 4.3% during the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock worth $289,000 after buying an additional 1,795 shares during the period. Green Alpha Advisors LLC lifted its position in Recursion Pharmaceuticals by 2.9% during the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock worth $427,000 after acquiring an additional 1,800 shares during the period. Interchange Capital Partners LLC grew its stake in Recursion Pharmaceuticals by 7.3% during the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after purchasing an additional 2,349 shares during the last quarter. Amalgamated Bank increased its holdings in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares during the period. Finally, Victory Capital Management Inc. boosted its position in Recursion Pharmaceuticals by 13.5% in the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after buying an additional 2,598 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on RXRX. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, November 7th. Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. Finally, Jefferies Financial Group lowered their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.